Target Group (CBDY) Q2: Revenue Down, Net Loss, $10.4M Related‑Party Debt, Liquidity Risk

Snapshot - Target Group Inc. (PINK: CBDY) - Q2 / H1 2025 results from Form 10‑Q (unaudited).

What's happening inside the company (quick take)

- The company is a vertically integrated cannabis operator (Canary Rx Inc. is the operating licensed producer) but is struggling with liquidity and heavy related‑party debt.

- Management consolidated JVCo into Canary after a settlement (April 27, 2023) and continues to rely on related‑party and shareholder loans to fund operations.

- Management reported the company's disclosure controls were not effective as of June 30, 2025.

Key income‑statement & balance‑sheet facts (as reported)

- Revenue: Q2 2025 $1,245,724 vs Q2 2024 $2,275,011; 6 months 2025 $2,646,163 vs 6 months 2024 $4,194,942.

- Cost of goods sold: Q2 2025 $(500,303); Gross profit Q2 2025 $745,421 (H1 2025 gross profit $1,516,248).

- Total operating expenses: Q2 2025 $608,294; H1 2025 $1,225,547.

- Other expense (net): Q2 2025 $356,897; H1 2025 $618,684 (includes interest & bank charges).

- Net (loss) income: Q2 2025 $(219,770) vs Q2 2024 $666,664; H1 2025 $(327,983) vs H1 2024 $473,496.

- Comprehensive (loss): Q2 2025 $(411,832); H1 2025 $(522,829).

- Earnings per share (basic & diluted): Q2 2025 $(0.0004); H1 2025 $(0.0005). Weighted avg. shares: 617,025,999.

- Cash (June 30, 2025): $837,497; Restricted cash: $8,430; Cash + restricted: $845,927 (down from $1,877,759 at 2025 year‑start).

- Total assets: $6,590,715 (Dec 31, 2024: $7,573,533). Total liabilities: $13,621,173 (Dec 31, 2024: $14,081,162).

- Payable to related parties: $10,402,612 (June 30, 2025) - up from $9,854,719 at Dec 31, 2024.

- Working capital deficit: $10,357,203 (June 30, 2025).

- Accumulated deficit: $(31,274,827). Stockholders' deficiency: $(7,030,458).

- Inventory: $976,513. Accounts receivable (net): $311,894. Accounts payable and accrued liabilities: $2,092,023.

- Lease liabilities (PV): $1,115,260 (current $161,520; non‑current $953,740).

- Convertible promissory notes principal outstanding: $480; derivative liability: $10,285; warrant liability: $7; warrants outstanding: 10,100,002.

- Cash paid for interest (H1 2025): $1,588,272 (very large interest cash outflow).

Positive aspects (income statement & operations)

- The business still generates product sales: H1 2025 revenue $2,646,163 (cannabis products sold to 12 customers).

- Strong gross margins on reported sales: gross profit H1 2025 $1,516,248 (margin roughly in the ~57% range - company retains significant margin before operating and financing costs).

- Depreciation is a material non‑cash charge (H1 2025 $445,418) - part of operating expense growth is non‑cash.

- Management reduced some operating expenses year‑over‑year (H1 operating expenses slightly lower versus prior year on a total basis: $1,225,547 vs $1,266,684).

Negative aspects (income statement & underlying risks)

- Revenue is declining YoY: Q2 2025 down vs Q2 2024; H1 2025 down vs H1 2024 - top line contraction is a red flag for growth and cash‑generation.

- The company moved from net income (H1 2024 $473,496) to net loss (H1 2025 $(327,983)) - driven by lower revenue and large finance charges / FX losses.

- Heavy interest and bank charges: interest & bank charges H1 2025 $514,736 and cash interest paid H1 2025 $1,588,272 - financing costs are materially eroding results and consuming cash.

- Large related‑party payables ($10.4M) and significant shareholder loan tranches (total maximum CAD amounts listed) - dependence on related‑party financing increases risk and may limit independent strategic options.

- Working capital deficit $10.36M and stockholders' deficiency $(7.03M) - the company discloses substantial doubt about going concern and will need additional financing to continue current operations.

- Foreign exchange losses are large (H1 2025 exchange loss $107,614) and foreign currency translation produced a material comprehensive loss.

- Controls deficiency: management concluded disclosure controls and procedures were not effective as of June 30, 2025 - increases reporting and operational risk.

- Legal contingencies and unissued shares/warrants commitments: litigation and royalty/share issuance commitments create additional potential dilution or cash outflows.

What investors should watch next

- Liquidity moves: any capital raise, loan amendments (noted CLI and shareholder loan negotiations) or material repayments - company needs fresh capital or debt restructuring to resolve working capital deficit.

- Interest cash outflows and whether financing costs are refinanced or reduced - current interest cash paid ($1.59M H1) is unsustainable vs current cash balance.

- Revenue trend and customer concentration (12 customers) - need stable / growing sales to cover fixed costs and financing charges.

- Related‑party balances and definitive terms for repayment/extension (company flagged ongoing discussions and an August 11, 2025 amendment to shareholder loan was filed).

- Any material change in internal controls, legal outcomes, or asset sales (inventory, IP, JV assets) that could change liquidity or capital structure.

Bottom line: Target Group Inc. (PINK: CBDY) still sells cannabis products and reports healthy gross margins, but declining revenue, large financing costs, growing related‑party liabilities, a working‑capital shortfall, and an accumulated deficit raise substantial going‑concern risk. Investors should prioritize liquidity and debt‑restructuring news and monitor next financing or operational turnaround indicators closely.